SubsidieMeestersThe OVAL study for VB-111 treatment of platinum-resistant ovarian cancer
VBL Therapeutics aims to finalize a Phase 3 trial for VB-111, a novel anti-cancer gene therapy targeting tumor blood supply and immune response, starting with ovarian cancer treatment.
Projectdetails
Introduction
VBL therapeutics is a late-stage clinical biopharmaceutical company focused on first-in-class treatments for cancer.
Product Candidate
VBL's lead oncology product candidate, VB-111, is an innovative targeted anti-cancer gene therapy with potential to treat a wide range of solid tumors.
Mechanism of Action
Most cancer therapies aim to target tumor cells while sparing normal cells, but tumors are heterogeneous and often develop resistance to treatment. Instead of targeting the tumor directly, VB-111 targets the tumor environment by:
- Disrupting the blood vessels that supply blood to the tumor
- Recruiting the immune system into the tumor
This dual mechanism of action, together with an excellent safety profile, makes VB-111 a game-changer.
Indication and Clinical Trial
VBL is pursuing Ovarian Cancer as the first indication for VB-111. In the scope of this project, VBL will finalize a Phase 3 potential-registration clinical trial, the OVAL study, as well as execute all the necessary steps towards final regulatory approvals and commercialization.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.500.000 |
| Totale projectbegroting | € 7.037.500 |
Tijdlijn
| Startdatum | 1-4-2022 |
| Einddatum | 31-3-2024 |
| Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- VASCULAR BIOGENICS LTDpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Development of a cell immunotherapy targeting non-conventional tumor antigens in ovarian cancerErVaccine aims to develop TCR-OV1, a novel TCR-T cell therapy targeting cancer-specific antigens to improve early detection and treatment outcomes for ovarian cancer patients. | EIC Accelerator | € 2.499.999 | 2024 | Details |
First-in-class anti-PVR mAb NTX1088 - a novel oncology drug that unlocks the power of human immune system and revolutionizes cancer careNectin Therapeutics is developing NTX1088, a monoclonal antibody that activates the immune system against cancer, currently in Phase I trials to improve patient outcomes in oncology. | EIC Accelerator | € 2.499.998 | 2024 | Details |
A Novel ‘Radiotherapy from Within’ Platform Technology for the Targeted Treatment of Solid Tumours Called ‘BAT-90’BetaGlue's BAT-90 is a personalized radiotherapy platform that targets solid tumors like HCC and PDAC, minimizing off-target effects through percutaneous administration, showing promising safety and effectiveness. | EIC Accelerator | € 2.499.999 | 2024 | Details |
The first IVDR-approved commercial software solutions for AI-powered RNA-based companion and precision cancer diagnostics of acute myeloid leukaemia and bladder cancerQlucore aims to revolutionize precision oncology by developing AI-driven diagnostic software for cancer, enhancing accuracy in gene analysis and improving survival rates across Europe. | EIC Accelerator | € 2.491.650 | 2024 | Details |
Clinical validation of NANO-PL: a hydrogel-based formulation of a small molecule for a highly targeted therapy against Glioblastoma Multiforme (GBM)NANO-PL is a hydrogel-based, one-time treatment for glioblastoma that shows promising safety and efficacy, including tumor eradication and improved survival rates in preclinical models. | EIC Accelerator | € 2.499.999 | 2024 | Details |
Development of a cell immunotherapy targeting non-conventional tumor antigens in ovarian cancer
ErVaccine aims to develop TCR-OV1, a novel TCR-T cell therapy targeting cancer-specific antigens to improve early detection and treatment outcomes for ovarian cancer patients.
First-in-class anti-PVR mAb NTX1088 - a novel oncology drug that unlocks the power of human immune system and revolutionizes cancer care
Nectin Therapeutics is developing NTX1088, a monoclonal antibody that activates the immune system against cancer, currently in Phase I trials to improve patient outcomes in oncology.
A Novel ‘Radiotherapy from Within’ Platform Technology for the Targeted Treatment of Solid Tumours Called ‘BAT-90’
BetaGlue's BAT-90 is a personalized radiotherapy platform that targets solid tumors like HCC and PDAC, minimizing off-target effects through percutaneous administration, showing promising safety and effectiveness.
The first IVDR-approved commercial software solutions for AI-powered RNA-based companion and precision cancer diagnostics of acute myeloid leukaemia and bladder cancer
Qlucore aims to revolutionize precision oncology by developing AI-driven diagnostic software for cancer, enhancing accuracy in gene analysis and improving survival rates across Europe.
Clinical validation of NANO-PL: a hydrogel-based formulation of a small molecule for a highly targeted therapy against Glioblastoma Multiforme (GBM)
NANO-PL is a hydrogel-based, one-time treatment for glioblastoma that shows promising safety and efficacy, including tumor eradication and improved survival rates in preclinical models.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Macrophage-based immunotherapy of platinum-resistant ovarian cancerThe MACOV project aims to develop a groundbreaking macrophage-based therapy for platinum-resistant ovarian cancer, preparing it for Phase I clinical trials through comprehensive pre-clinical efficacy and safety studies. | EIC Transition | € 2.499.998 | 2022 | Details |
Trial BoosterVitroScan en Imuno ontwikkelen een screeningsplatform om de effectiviteit van immuuntherapie bij blaaskanker te voorspellen, waardoor patiëntselectie voor klinische studies verbetert. | Mkb-innovati... | € 347.410 | 2022 | Details |
Systemic delivery of oncolytic herpes simplex viruses retargeted to cancer-specific receptors. Virus optimization and business planning.This project aims to enhance systemic delivery of innovative oncolytic herpesviruses targeting HER2-positive tumors, facilitating clinical trials and commercialization to improve metastatic cancer treatment. | ERC Proof of... | € 150.000 | 2022 | Details |
STA-OPHet project ontwikkelt een op maat gemaakte therapie voor eierstokkanker om de levensduur en kwaliteit van leven van patiënten te verbeteren. | 1.1 - Het ve... | € 482.805 | 2023 | Details |
Lectibodies to Eliminate TumoursThis project aims to develop lectibodies for targeted delivery of therapeutics to neuroblastoma by harnessing GSL-binding proteins, potentially revolutionizing cancer treatment. | ERC Proof of... | € 150.000 | 2022 | Details |
Macrophage-based immunotherapy of platinum-resistant ovarian cancer
The MACOV project aims to develop a groundbreaking macrophage-based therapy for platinum-resistant ovarian cancer, preparing it for Phase I clinical trials through comprehensive pre-clinical efficacy and safety studies.
Trial Booster
VitroScan en Imuno ontwikkelen een screeningsplatform om de effectiviteit van immuuntherapie bij blaaskanker te voorspellen, waardoor patiëntselectie voor klinische studies verbetert.
Systemic delivery of oncolytic herpes simplex viruses retargeted to cancer-specific receptors. Virus optimization and business planning.
This project aims to enhance systemic delivery of innovative oncolytic herpesviruses targeting HER2-positive tumors, facilitating clinical trials and commercialization to improve metastatic cancer treatment.
STA-OP
Het project ontwikkelt een op maat gemaakte therapie voor eierstokkanker om de levensduur en kwaliteit van leven van patiënten te verbeteren.
Lectibodies to Eliminate Tumours
This project aims to develop lectibodies for targeted delivery of therapeutics to neuroblastoma by harnessing GSL-binding proteins, potentially revolutionizing cancer treatment.